Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FLOT Neoadjuvant Chemotherapy for Resectable Advanced Esophageal Squamous Cell Carcinoma
jRCTs051250037Phase 2Recruiting
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin and docetaxel in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: overall response rate. Started Jun 2025; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCTs051250037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250037.